Skip to content

LeMaitre Vascular

US · LMAT #2839 by market cap Listed 1970
73.61 -1.25 -1.67%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Fair Value how this is computed

Below fair value
90.73 fair value ≈ 114.68 138.63
  • Implied fair-value range of 90.73-138.63, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -35.8% below the average-multiple fair value of 114.68.

Valuation each multiple against its own 5-year range

P/B ratio 4.15 Cheap vs history 22nd percentile
5-year average 5.00 · #35 of 51 in Medical Instruments & Supplies
P/E ratio 28.47 Cheap vs history 3rd percentile
5-year average 45.51 · forward 25.02 · #14 of 27 in Medical Instruments & Supplies
P/S ratio 7.05 In line with history 34th percentile
5-year average 7.91 · forward 6.38 · #41 of 50 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
LeMaitre Vascular (LMAT) 1.68B 26.77 3.90 1.29%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value88.70 Economic moatNarrow UncertaintyLow

Trading 20.5% below Morningstar's fair value estimate.

Fair value

LeMaitre Vascular Inc receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 12% discount to our quantitative fair value estimate of $88.70 per share, which is reinforced by this estimate's low uncertainty rating.

The firm's solid growth increases our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 12.3% falls in the top 30% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

Conversely, the firm's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, ranks in the top 45% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

LeMaitre Vascular discussion 0 comments

Add a comment